Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies

1
Ovarian Cancer Therapeutics in Major Developed
Markets to 2020 - Late-Stage Pipeline Focuses on
Improved Progression Free-Surival and Targeted
Therapies
Single User License - 3500 Site User
License - 7000 Corporate User License -
10500 Publication Date - May 2014 Pages -
148 To know more details, email to
debora_at_reportstack.com
2
Summary

• The current Ovarian cancer therapeutics market is
  dominated by the use of generics predominately
  carboplatin and paclitaxel, which are used in
  combination for the treatment of
  platinum-sensitive disease (both first-line and
  recurrent). Initial treatment with platinum-based
  therapy is usually effective, with approximately
  70 of patients entering remission. However, even
  with extended progression free-survival of 24
  months, almost all patients relapse, and after
  successive periods of remission and relapse
  either die or progress to platinum-resistant
  disease, for which the prognosis is poor. There
  is a clear gap in the market for maintenance
  therapies to extend the initial high rates of
  remission, and hopefully stimulate long-term
  remission in patients. As well as a gap for more
  effective treatment options in platinum-resistant
  or refractory patients.

3
Scope
- A brief introduction to ovarian cancer,
including the diseases pathogenesis, risk
factors and diagnosis.- In-depth analysis of the
drug combinations used in the treatment of
ovarian cancer, including analyses of their
safety, efficacy, and place in the disease
treatment algorithm. This includes a heat map
comparing the drug combination in terms of safety
and efficacy.- Comprehensive review of the
pipeline for ovarian cancer therapies, including
individual analysis of a number of late-stage
pipeline drugs that have the potential to enter
the market in the forecast period. The pipeline
is analyzed on the basis of phase distribution,
molecule types and molecular targets, as well as
administration routes.- Discussion of the
drivers and barriers for market growth.
4
Key Benefits
- Understanding the efficacy and safety of the
current monotherapies and drug combinations used
in the treatment of ovarian cancer, with an
in-depth analysis of the disease treatment
algorithm.- Understand the key signalling
pathways and molecular targets currently inder
investigation in drug development for ovarian
cancer- Understand the vast scope of the
pipeline, including which molecule types and
mechanisms of action are prominent.- Observe the
trends in clinical trial duration and size
amongst clinical phases and molecule types, and
use the clinical trial failure rate analysis to
assess the risk profiles of current and/or future
developmental programs for pancreatic cancer
therapeutics.
5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com